Buglioni S - Search Results

1

c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings.

Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G. Biroccio A, et al. Among authors: buglioni s. Am J Pathol. 2001 Apr;158(4):1289-99. doi: 10.1016/S0002-9440(10)64080-1. Am J Pathol. 2001. PMID: 11290547 Free PMC article.

2

An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples.

Bironzo P, Pepe F, Russo G, Pisapia P, Gragnano G, Aquino G, Bessi S, Buglioni S, Bartoccini F, Ferrero G, Bresciani MA, Francia di Celle P, Sibona F, Giusti A, Movilia A, Farioli RM, Santoro A, Salemi D, Scarpino S, Galafate D, Tommasi S, Lacalamita R, Seminati D, Sajjadi E, Novello S, Pagni F, Troncone G, Malapelle U. Bironzo P, et al. Among authors: buglioni s. Diagnostics (Basel). 2023 Feb 8;13(4):629. doi: 10.3390/diagnostics13040629. Diagnostics (Basel). 2023. PMID: 36832117 Free PMC article.

3

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: buglioni s. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.

4

Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2.

Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M. Buglioni S, et al. Int J Cancer. 1999 Dec 22;84(6):545-52. doi: 10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2. Int J Cancer. 1999. PMID: 10567896 Free article.

5

Prognostic relevance of altered Fas (CD95)-system in human breast cancer.

Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM. Mottolese M, et al. Among authors: buglioni s. Int J Cancer. 2000 Mar 20;89(2):127-32. doi: 10.1002/(sici)1097-0215(20000320)89:2<127::aid-ijc5>3.0.co;2-4. Int J Cancer. 2000. PMID: 10754489 Free article.

6

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nisticò C, Di Filippo F, Vasselli S, Vici P, Botti C. Mottolese M, et al. Among authors: buglioni s. J Cancer Res Clin Oncol. 2000 Dec;126(12):722-9. doi: 10.1007/pl00008478. J Cancer Res Clin Oncol. 2000. PMID: 11153146

7

Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.

Di Modugno F, Buglioni S, Mottolese M, Bello DD, Cascioli S, Chersi A, Santoni A, Nisticò P. Di Modugno F, et al. Among authors: buglioni s. J Immunother. 2001 May-Jun;24(3):221-31. J Immunother. 2001. PMID: 11394499

8

Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.

Di Modugno F, Buglioni S, Mottolese M, Del Bello D, Cascioli S, Chersi A, Santoni A, Nisticò P. Di Modugno F, et al. Among authors: buglioni s. J Immunother (1991). 2001 May;24(3):221-231. J Immunother (1991). 2001. PMID: 11395637

9

p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.

Buglioni S, D'Agnano I, Vasselli S, Perrone Donnorso R, D'Angelo C, Brenna A, Benevolo M, Cosimelli M, Zupi G, Mottolese M. Buglioni S, et al. Am J Clin Pathol. 2001 Sep;116(3):360-8. doi: 10.1309/V7UW-UT2E-JVYH-DGWK. Am J Clin Pathol. 2001. PMID: 11554164

10

Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity.

Del Bufalo D, Trisciuoglio D, Biroccio A, Marcocci L, Buglioni S, Candiloro A, Scarsella M, Leonetti C, Zupi G. Del Bufalo D, et al. Among authors: buglioni s. J Cell Biochem. 2001 Aug 21-Sep 5;83(3):473-83. doi: 10.1002/jcb.1245. J Cell Biochem. 2001. PMID: 11596115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page